Outlook Therapeutics Inc Stock Shares Owned By Insiders
| OTLK Stock | USD 5.03 0.10 1.95% |
OUTLOOK THERAPEUTICS INC fundamentals help investors to digest information that contributes to OUTLOOK THERAPEUTICS's financial success or failures. It also enables traders to predict the movement of OUTLOOK Stock. The fundamental analysis module provides a way to measure OUTLOOK THERAPEUTICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to OUTLOOK THERAPEUTICS stock.
OUTLOOK | Shares Owned By Insiders |
OUTLOOK THERAPEUTICS INC Company Shares Owned By Insiders Analysis
OUTLOOK THERAPEUTICS's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current OUTLOOK THERAPEUTICS Shares Owned By Insiders | 35.58 % |
Most of OUTLOOK THERAPEUTICS's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, OUTLOOK THERAPEUTICS INC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
OUTLOOK Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for OUTLOOK THERAPEUTICS is extremely important. It helps to project a fair market value of OUTLOOK Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since OUTLOOK THERAPEUTICS's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of OUTLOOK THERAPEUTICS's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of OUTLOOK THERAPEUTICS's interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 35.58% of OUTLOOK THERAPEUTICS INC are shares owned by insiders. This is 134.39% higher than that of the Biotechnology sector and 150.92% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
OUTLOOK Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OUTLOOK THERAPEUTICS's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of OUTLOOK THERAPEUTICS could also be used in its relative valuation, which is a method of valuing OUTLOOK THERAPEUTICS by comparing valuation metrics of similar companies.OUTLOOK THERAPEUTICS is currently under evaluation in shares owned by insiders category among its peers.
OUTLOOK THERAPEUTICS Current Valuation Drivers
We derive many important indicators used in calculating different scores of OUTLOOK THERAPEUTICS from analyzing OUTLOOK THERAPEUTICS's financial statements. These drivers represent accounts that assess OUTLOOK THERAPEUTICS's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of OUTLOOK THERAPEUTICS's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 52.2M | 331.3M | 258.7M | 55.3M | 49.8M | 91.1M | |
| Enterprise Value | 48.5M | 328.7M | 252.3M | 67.5M | 60.7M | 97.1M |
OUTLOOK THERAPEUTICS ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, OUTLOOK THERAPEUTICS's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to OUTLOOK THERAPEUTICS's managers, analysts, and investors.Environmental | Governance | Social |
OUTLOOK Fundamentals
| Return On Equity | -0.0365 | ||||
| Return On Asset | -0.84 | ||||
| Current Valuation | 119.69 M | ||||
| Shares Outstanding | 23.66 M | ||||
| Shares Owned By Insiders | 35.58 % | ||||
| Shares Owned By Institutions | 35.64 % | ||||
| Number Of Shares Shorted | 3.23 M | ||||
| Price To Earning | (1.24) X | ||||
| Price To Book | 10.19 X | ||||
| Price To Sales | 13.27 X | ||||
| Gross Profit | (42.33 M) | ||||
| EBITDA | (57.38 M) | ||||
| Net Income | (58.98 M) | ||||
| Cash And Equivalents | 26.02 M | ||||
| Cash Per Share | 0.12 X | ||||
| Total Debt | 35.56 M | ||||
| Debt To Equity | 0.52 % | ||||
| Current Ratio | 2.04 X | ||||
| Book Value Per Share | (3.58) X | ||||
| Cash Flow From Operations | (42.97 M) | ||||
| Short Ratio | 12.33 X | ||||
| Earnings Per Share | (5.89) X | ||||
| Target Price | 39.5 | ||||
| Number Of Employees | 24 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 118.99 M | ||||
| Total Asset | 32.3 M | ||||
| Retained Earnings | (467.92 M) | ||||
| Working Capital | (15.75 M) | ||||
| Current Asset | 4.12 M | ||||
| Current Liabilities | 28.27 M | ||||
| Net Asset | 32.3 M |
About OUTLOOK THERAPEUTICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OUTLOOK THERAPEUTICS INC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OUTLOOK THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OUTLOOK THERAPEUTICS INC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out OUTLOOK THERAPEUTICS Piotroski F Score and OUTLOOK THERAPEUTICS Altman Z Score analysis. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. If investors know OUTLOOK will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OUTLOOK THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.89) | Revenue Per Share 0.119 | Quarterly Revenue Growth 6.583 | Return On Assets (0.84) | Return On Equity (0.04) |
The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OUTLOOK THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if OUTLOOK THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OUTLOOK THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.